Valuation : Galapagos NV

Market Cap 1.6B 1.86B 1.51B 1.37B 2.58B 176B 2.6B 17.82B 6.94B 89.68B 6.97B 6.82B 297B P/E 2026 *
-13x
P/E 2027 * -6.59x
Enterprise Value -828M -960M -779M -710M -1.33B -91.1B -1.34B -9.21B -3.58B -46.34B -3.6B -3.53B -154B EV / Sales 2026 *
-8.73x
EV / Sales 2027 * 1.12x
Free-Float
74.64%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 11/05/2025
Director of Finance/CFO 41 06/07/2025
Chief Operating Officer - 31/05/2026
Director TitleAgeSince
Director/Board Member 63 21/10/2019
Director/Board Member 49 06/10/2024
Director/Board Member 53 11/05/2025
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 1.85B
+0.21%-2.69%+1.19%+17.32% 49.81B
+2.09%-0.71%+452.73%+498.77% 44.06B
-1.09%-0.41%+35.40%+15.17% 42.99B
-0.26%-4.71%+17.19%+71.67% 40.88B
-0.48%-0.84%+16.25%+49.80% 33.11B
-1.06%+2.87% - - 17.27B
-1.81%-5.02%+22.65%+113.24% 16.58B
-1.35%-3.40%+10.13%+26.34% 14.63B
-2.05%-5.14%+72.89%+34.69% 13.76B
Average -0.74%-2.11%+78.55%+103.38% 30.34B
Weighted average by Cap. -0.50%-1.88%+94.97%+120.43%

Financials

2026 *2027 *
Net sales 94.87M 110M 89.24M 81.3M 153M 10.44B 154M 1.05B 411M 5.31B 413M 404M 17.6B 80.29M 93.08M 75.53M 68.81M 129M 8.83B 130M 893M 348M 4.49B 349M 342M 14.9B
Net income -40.7M -47.18M -38.28M -34.87M -65.58M -4.48B -65.94M -453M -176M -2.28B -177M -173M -7.55B -213M -247M -200M -182M -343M -23.4B -345M -2.37B -921M -11.9B -926M -906M -39.47B
Net Debt -2.43B -2.82B -2.29B -2.08B -3.92B -267B -3.94B -27.03B -10.52B -136B -10.58B -10.35B -451B -1.51B -1.75B -1.42B -1.3B -2.44B -166B -2.45B -16.82B -6.55B -84.64B -6.58B -6.44B -281B
Logo Galapagos NV
Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B